Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Chemotherapy in Treating Patients With Progressive or Recurrent Brain Tumors

Study:

A Phase I/II Trial Of MGI114 For Treatment Of Patients With Recurrent Malignant Gliomas

Rationale:

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Purpose:

Phase I/II trial to study the effectiveness of irofulven in treating patients who have progressive or recurrent astrocytoma, oligodendroglioma, or glioblastoma multiforme.

Study Status: Completed

Recruiting:
n/a

Condition Intervention Phase
Brain and Central Nervous System Tumors Drug: irofulven Phase 1/Phase 2

Verified by National Cancer Institute (NCI) September, 2003

Sponsored by: National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00012038

Study Type: Interventional

Study Design: Primary Purpose: Treatment

Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States

Steven S. Rosenfeld, MD, PhD., Study Chair

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.